Focused On-demand Library for Phenazine biosynthesis-like domain-containing protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P30039

UPID:

PBLD_HUMAN

Alternative names:

MAWD-binding protein; Unknown protein 32 from 2D-page of liver tissue

Alternative UPACC:

P30039; A8MZJ3; C9JIM0; Q9HCC2

Background:

The Phenazine biosynthesis-like domain-containing protein, also known as MAWD-binding protein and Unknown protein 32 from 2D-page of liver tissue, represents a unique entity in the proteomic landscape. Its nomenclature hints at a potential role in the biosynthesis of phenazines, a class of nitrogen-containing heterocyclic compounds known for their diverse biological activities.

Therapeutic significance:

Understanding the role of Phenazine biosynthesis-like domain-containing protein could open doors to potential therapeutic strategies. Its association with phenazine biosynthesis suggests a possible impact on microbial communities and infectious diseases, offering a novel angle for drug discovery efforts.